Johnson & Johnson [NYSE: JNJ] traded at a low on 01/10/22, posting a -0.49 loss after which it closed the day’ session at $173.09. The company report on January 6, 2022 that Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States.
Johnson & Johnson (NYSE: JNJ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot of the Johnson & Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions. The study was sponsored by the Janssen Pharmaceutical Companies of Johnson & Johnson and conducted in partnership with the Department of Science-Aetion, Inc, and the Division of Pharmacoepidemiology, Department of Medicine at Brigham and Women’s Hospital and Harvard Medical School.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
“We continue to undertake extensive efforts to study the durability of protection offered by the Johnson & Johnson vaccine amidst the ever-changing COVID-19 pandemic,” said Mathai Mammen, M.D., Ph.D., Executive Vice President, Pharmaceuticals, Janssen Research & Development LLC, Johnson & Johnson. “While these are rapidly evolving data, we are seeing vaccine effectiveness against COVID-19-related hospitalization of approximately 80 percent from a single shot of the Johnson & Johnson vaccine, and this level of protection holds steady across the length of time studied thus far – up to six months. The robust and sustained durability of our COVID-19 vaccine reflects its unique underlying immunology. We previously reported that our vaccine induces a strong antibody response as well as an especially strong increase in T-cells that is consistent across variants, including Omicron.”.
The results of the trading session contributed to over 7621418 shares changing hands. Over the past one week, the price volatility of Johnson & Johnson stands at 1.16% while the volatility over the past one month is 1.31%.
The market cap for JNJ stock reached $449.60 billion, with 2.63 billion shares outstanding and 2.63 billion shares in the current float. Compared to the average trading volume of 7.31M shares, JNJ reached a trading volume of 7621418 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Johnson & Johnson [JNJ]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JNJ shares is $186.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JNJ stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Johnson & Johnson shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 17, 2021. While these analysts kept the previous recommendation, Citigroup raised their target price from $192 to $195. The new note on the price target was released on December 15, 2021, representing the official price target for Johnson & Johnson stock. Previously, the target price had yet another raise to $187, while Morgan Stanley analysts kept a Equal-Weight rating on JNJ stock.
The Average True Range (ATR) for Johnson & Johnson is set at 2.34, with the Price to Sales ratio for JNJ stock in the period of the last 12 months amounting to 4.92. The Price to Book ratio for the last quarter was 6.49, with the Price to Cash per share for the same quarter was set at 11.93. Price to Free Cash Flow for JNJ in the course of the last twelve months was 38.89 with Quick ratio for the last quarter at 1.10.
How has JNJ stock performed recently?
Johnson & Johnson [JNJ] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.90. With this latest performance, JNJ shares gained by 4.33% in over the last four-week period, additionally plugging by 2.26% over the last 6 months – not to mention a rise of 8.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JNJ stock in for the last two-week period is set at 62.98, with the RSI for the last a single of trading hit 64.15, and the three-weeks RSI is set at 61.17 for Johnson & Johnson [JNJ]. The present Moving Average for the last 50 days of trading for this stock 165.60, while it was recorded at 172.39 for the last single week of trading, and 166.78 for the last 200 days.
Johnson & Johnson [JNJ]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Johnson & Johnson [JNJ] shares currently have an operating margin of +24.79 and a Gross Margin at +66.09. Johnson & Johnson’s Net Margin is presently recorded at +17.82.
Return on Total Capital for JNJ is now 21.80, given the latest momentum, and Return on Invested Capital for the company is 16.02. Return on Equity for this stock inclined to 23.97, with Return on Assets sitting at 8.85. When it comes to the capital structure of this company, Johnson & Johnson [JNJ] has a Total Debt to Total Equity ratio set at 57.47. Additionally, JNJ Total Debt to Total Capital is recorded at 36.50, with Total Debt to Total Assets ending up at 20.79. Long-Term Debt to Equity for the company is recorded at 53.31, with the Long-Term Debt to Total Capital now at 33.86.
Reflecting on the efficiency of the workforce at the company, Johnson & Johnson [JNJ] managed to generate an average of $109,398 per employee. Receivables Turnover for the company is 5.89 with a Total Asset Turnover recorded at a value of 0.50.Johnson & Johnson’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.30.
Earnings analysis for Johnson & Johnson [JNJ]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JNJ. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Johnson & Johnson go to 8.19%.
Insider trade positions for Johnson & Johnson [JNJ]
There are presently around $309,831 million, or 70.00% of JNJ stock, in the hands of institutional investors. The top three institutional holders of JNJ stocks are: VANGUARD GROUP INC with ownership of 233,479,175, which is approximately 0.884% of the company’s market cap and around 0.07% of the total institutional ownership; BLACKROCK INC., holding 195,038,467 shares of the stock with an approximate value of $33.76 billion in JNJ stocks shares; and STATE STREET CORP, currently with $24.61 billion in JNJ stock with ownership of nearly 0.097% of the company’s market capitalization.
1,612 institutional holders increased their position in Johnson & Johnson [NYSE:JNJ] by around 55,210,224 shares. Additionally, 1,426 investors decreased positions by around 39,833,764 shares, while 346 investors held positions by with 1,694,956,442 shares. The mentioned changes placed institutional holdings at 1,790,000,430 shares, according to the latest SEC report filing. JNJ stock had 101 new institutional investments in for a total of 5,296,395 shares, while 90 institutional investors sold positions of 1,675,743 shares during the same period.